GlassScriptPhysician profile
Desiree Lilley
NPI 1790550408
$4,138.26
in general payments reported to CMS, 2019-2025
37 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,045 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,138.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $493.93 | 2024-2025 | |
| Abbvie INC. | $459.97 | 2024-2025 | |
| Amgen INC. | $367.22 | 2024-2025 | Evenity, Prolia, Repatha |
| Axsome Therapeutics, INC. | $326.86 | 2024-2025 | Sunosi, Auvelity, Symbravo |
| Novo Nordisk INC | $234.38 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $194.73 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $183.75 | 2024-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $177.15 | 2024-2025 | |
| Glaxosmithkline, LLC. | $173.72 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $163.66 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.98 | 2024-2025 | Xifaxan |
| Mannkind Corporation | $138.08 | 2024-2025 | |
| Astellas Pharma US INC | $115.26 | 2024-2025 | Veozah |
| Radius Health, INC. | $92.69 | 2024 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.78 | 2024-2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.35 | 2024-2025 | Jardiance |
| Antares Pharma, INC. | $60.38 | 2024-2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $52.24 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $51.77 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $50.20 | 2025 | Gemtesa |
| Exact Sciences Corporation | $49.56 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $45.38 | 2024 | Rexulti, Vyepti |
| Cequr Corporation | $43.83 | 2024-2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $40.41 | 2024-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $39.23 | 2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $31.79 | 2024-2025 | Ajovy |
| Eisai INC. | $27.79 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $25.20 | 2025 | Opsumit, Uptravi |
| Novavax INC | $24.89 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Organon LLC | $24.73 | 2024 | |
| Harmony Biosciences LLC | $23.28 | 2025 | |
| Viatris Specialty LLC | $22.56 | 2025 | Yupelri |
| Ars Pharmaceuticals Operations, INC. | $22.30 | 2025 | Neffy |
| Mylan Specialty L.P. | $19.63 | 2024 | Yupelri |
| Dexcom, INC. | $18.89 | 2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $16.31 | 2024 | Evkeeza |
| Agios Pharmaceuticals, INC. | $14.38 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Lilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.